Riskpilot← Back to searchSign inGet full accessZygotene AB
ABActiveOrg 5568304694Geijersgatan 2 BMedical specialists activities · NACE 8622Est. 20100 employees
Revenue 2024
SEK 0
EBITDA margin
—
-17% vs 2023
Equity ratio
97.7%
Financial strength
Net profit 2024
SEK 44K
-75% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -138K | -17% |
| Net profit | SEK 44K | -75% |
| Total assets | SEK 25,2M | +0% |
| Equity | SEK 24,6M | -1% |
| Employees | 0 | — |
Legal name
Zygotene AB
Org number
5568304694
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
8 december 2010
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Aktiebolaget ska bedriva sjukvård, forskning, läromedels- framställning, teknologi, medicinsk konsultverksamhet, läkarpraktik, handel med värdepapper och fastigheter och därmed förenlig verksamhet.
Address
Geijersgatan 2 B
Email
pia@saldeen.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −181 | −62 | 142 | −118 | −138 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −181 | −62 | 142 | −118 | −138 |
| Net financials | 2 617 | 2 715 | 796 | −13 | −38 |
| Profit before tax | 2 789 | 3 311 | 1 290 | 277 | 143 |
| Tax | −58 | −48 | −113 | −99 | −99 |
| Net profit | 2 731 | 3 263 | 1 177 | 178 | 44 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 22 179 | 24 893 | 25 519 | 25 307 | 25 194 |
| Equity | 20 727 | 23 806 | 24 797 | 24 780 | 24 619 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 277 | 148 | 136 | 185 | 231 |
| Total debt | 277 | 148 | 136 | 185 | 231 |
EBITDA margin
-13800000.0%
This company
15.8%
Market median
-87341872% vs market
20202024
Equity ratio
97.7%
This company
38.2%
Market median
+156% vs market
20202024
Return on equity
0.2%
This company
18.4%
Market median
-99% vs market
20202024
Net profit margin
4400000.0%
This company
8.1%
Market median
+54320888% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.02×
This company
0.62×
Market median
+97% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
MA | Audit | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2025 | |
| Board of Directors | 2022 | |
| Former (1) | ||
| Deputy Board Member | 2022 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Zygotene AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Marie Ann-Christin Hansson | Audit | 0 companies |
| Tom Gustaf Per Saldeen | Deputy Board Member | 0 companies |
| Rakel Alicia Märtha Sofie Saldeen | Deputy Board Member | 0 companies |
| Pia Maria Sofie Saldeen | Board of Directors | 0 companies |